Treatment of Recurrent Tuberculosis

Initial Evaluation and Treatment

The American Thoracic Society recommends obtaining immediate microbiological confirmation through sputum cultures and drug susceptibility tests for first- and second-line drugs in a reference laboratory for patients with recurrent tuberculosis 1, 2
The Centers for Disease Control and Prevention suggest performing rapid molecular tests, such as Xpert MTB/RIF, to detect resistance to rifampicin and isoniazid before modifying treatment 1, 2
The World Health Organization advises against modifying treatment without first obtaining samples, as this eliminates the opportunity to identify the resistance pattern 2

For patients who completed previous treatment with directly observed therapy (DOT) using a regimen with rifamycins, the majority of recurrences occur with sensitive organisms 1, 3, 4
The Infectious Diseases Society of America recommends restarting the standard intensive phase regimen, consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol, daily until sensitivity results are obtained 1, 3
All drugs should be administered via DOT 1

The European Respiratory Society suggests initiating an expanded regimen immediately if the patient presents with compromised immunity, limited respiratory reserve, or central nervous system involvement 1, 3, 4, 5
An expanded regimen should also be considered for patients with persistent bacilloscopy or circumstances where an inadequate regimen would have severe consequences 4, 5

In high-incidence settings or with inadequate infection control, consider exogenous reinfection with a new strain 1, 3, 6
If a source case with resistant TB is identified, base the empirical regimen on the source case's resistance profile 1, 3

The American College of Chest Physicians recommends adjusting the regimen immediately according to the resistance pattern once sensitivity results are available 1, 7
For patients with multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB), consult with a resistant TB expert 7
Monthly clinical evaluations and sputum cultures should be performed to identify adverse effects and assess adherence 8

The Centers for Disease Control and Prevention recommends that TB PCR can be used as part of the diagnostic workup for TB relapse, but it should not be used alone—microbiological culture with drug susceptibility testing remains essential and must be obtained before any treatment modifications 9, 10, 11
Exercise caution when interpreting PCR results at the time of suspected recurrence, as false-positive detection of M. tuberculosis DNA and rifampicin resistance have been reported, according to the World Health Organization 9, 10, 11
PCR cannot distinguish between viable and dead organisms, which is particularly problematic in relapse scenarios where residual DNA from prior infection may persist, as noted by the American Thoracic Society 9

Use PCR results to inform initial empiric treatment decisions while awaiting culture results, but interpret with caution given false-positive risk, as recommended by the Infectious Diseases Society of America 9, 10

For patients previously treated with directly observed therapy (DOT) using rifamycin-containing regimens, most relapses occur with susceptible organisms, according to the Centers for Disease Control and Prevention 9, 10
If PCR suggests rifampicin resistance, consider initiating an expanded empiric regimen containing at least 5 drugs if the patient is seriously ill, has extensive disease, or has compromised immunity, as recommended by the World Health Organization 9, 10

Patients with irregular prior treatment or self-administered therapy have substantially higher risk of acquired drug resistance, making comprehensive DST even more critical, as noted by the European Centre for Disease Prevention and Control 9, 10
In high-incidence settings, consider exogenous reinfection with a new strain rather than true relapse, according to the World Health Organization 9, 10
Do not interpret positive PCR as definitive proof of viable organisms in the relapse setting without culture confirmation, as recommended by the Infectious Diseases Society of America 9, 10